On subgroup analysis, RFA alone was associated with significantly worse overall survival when compared with TACE-RFA in patients of any age, with any tumor number, AFP level, alanine aminotransferase level, albumin level, total bilirubin level, tumor diameter of greater than 3 cm (HR, 3.20; 95% CI, 1.91-5.35; P < .001), and platelet count of less than 100 × 109 (HR, 4.81; 95% CI, 2.18-10.63; P < .001) (Figure 3). This evidence concerns the gene AFP and neoplasm.